[Federal Register Volume 59, Number 174 (Friday, September 9, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-22187]


[[Page Unknown]]

[Federal Register: September 9, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE
Department of the Army

 

Availability of Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Concerning Treatment of Filariasis

AGENCY: U.S. Army Medical Research, Development, Acquisition and 
Logistics Command, DOD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability for licensing of U.S. Patent No. 5,281,597, issued January 
25, 1994, and entitled ``Heterocyclic and Aromatic Thiosemicarbazones 
Useful in the Treatment of Filariasis.'' This patent has been assigned 
to the United States Government by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research, Development, 
Acquisitions and Logistics Command, ATTN: Staff Judge Advocate, Fort 
Detrick, Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT:
Mr. John F. Moran, Patent Attorney, (301) 619-2065 or telefax (301) 
619-7714.

SUPPLEMENTARY INFORMATION: The invention relates to the use of 
composition of matter and their pharmaceutically-acceptable acid 
addition salts of heterocyclic and aromatic thiosemicarbazones in the 
treatment of filariasis in mammals, including humans. The most 
effective of the series is filarizone, which completely destroys both 
macro- and microfilaria at therapeutic dose levels without causing 
apparent toxicity to the host.
Kenneth L. Denton,
Army Federal Register Liaison Officer.
[FR Doc. 94-22187 Filed 9-8-94; 8:45 am]
BILLING CODE 3710-08-M